ReviewTobacco prevention & cessation2025
Cost-effectiveness of smoke-free interventions: A systematic review.
Review in Tobacco prevention & cessation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of reducing nicotine in cigarettes on mortality, economic costs and major depression in the USA.Tobacco control · 2026Article
- Twenty years on from smoke-free legislation in Scotland: A secondary analysis of the Scottish Health Survey dataset (1998-2024) examining changes in household smoking rules, and salivary cotinine concentrations among non-smokers.Tobacco induced diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTobacco use imposes substantial global economic costs - estimated at $1803 to $1899 billion annually (1.76-1.85% of global gross domestic product) - through healthcare expenditures and productivity losses. In 2019, it contributed to approximately 8.70 million deaths and 229.77 million disability-adjusted life years (DALYs); secondhand smoke exposure added 1.31 million deaths and 37.01 million DALYs. While tobacco control efforts continue, evidence on the economic impacts of interventions remains limited. This study systematically reviews the cost-effectiveness of smoke-free interventions to inform policy.
methodsA systematic literature review was conducted following PRISMA guidelines and registered with PROSPERO (CRD42024521198). Searches conducted in January 2024 in PubMed, Web of Science, and Cochrane databases identified English-language economic evaluations of smoke-free interventions. Data were extracted using pre-defined checklists, and results were summarized using narrative synthesis. Studies were further assessed using the Consensus Health Economic Criteria (CHEC) and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) tools. Studies scoring <60% on CHEERS were excluded.
resultsOf 639 articles, 9 met the inclusion criteria. Most used healthcare or government perspectives (56%), 33% adopting a societal perspective. Interventions included public (44%), workplace, and school-based smoking bans. Studies were conducted in Vietnam, the US, Indonesia, Tanzania, Estonia, Denmark, India, and EU countries, employing economic models such as Markov models (44%). Time horizons ranged from one year to lifetime. Incremental cost-effectiveness ratios (ICERs) ranged from $7 per DALY averted to $17056 per life year gained. Most interventions were found to be cost-effective or dominant.
conclusionsPublic smoking bans consistently saved healthcare costs; workplace and school-based bans were also cost-effective, though context-dependent. This review suggests that smoking bans, particularly comprehensive smoke-free policies, should be prioritized by decision-makers as they demonstrate both health and economic benefits, proving to be cost-effective or even cost-saving public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.